利拉鲁肽可对抗大鼠心肌缺血再灌注损伤  

Liraglutide attenuates myocardial ischemia/reperfusion injury possibly through reducing cardiomyocytes apoptosis and oxidation in rats

作　　者：程向娟 王雄[1] 滕晓焕[1] 

机构地区：[1]山西医科大学第一医院心内科,太原030001

出　　处：《中华心血管病杂志》2015年第3期259-263,共5页Chinese Journal of Cardiology

基　　金：山西省回国留学人员科研资助项目（2012-050）

摘　　要：目的 探讨利拉鲁肽对大鼠心肌缺血再灌注损伤的作用及其机制.方法 SD大鼠24只,雄性,随机数字表法分为假手术组、缺血再灌注组（I/R组）和利拉鲁肽组,每组8只.通过结扎左冠状动脉前降支（LAD） 30 min再灌注2h建立大鼠心肌缺血再灌注损伤模型.苏木素伊红染色法光镜下观察大鼠心肌组织形态学改变,2,3,5-三苯基氯化四氮唑（TTC）染色法测定大鼠心肌梗死面积,免疫组织化学法和蛋白印迹法分别测定心肌组织中半胱氨酸天冬氨酸蛋白酶-3（caspase-3）和p53的表达,黄嘌呤氧化酶法测定血清超氧化物歧化酶（SOD）活性,硫代巴比妥酸法测定丙二醛（MDA）浓度.结果 苏木素伊红染色结果示利拉鲁肽组大鼠心肌损伤程度明显较I/R组轻.与I/R组比较,利拉鲁肽组大鼠心肌梗死面积较小[（44±8）％比（62±8）％,P＜0.05）],caspase-3表达水平较低（0.19±0.03比0.24±0.02,P＜0.05）,p53的表达水平较低（0.27±0.03比0.39±0.04,P＜0.05）,血清SOD活性较高（74.20±11.10比44.04±14.30,P＜0.05）,MDA浓度较低（4.41 ±1.07比8.72±2.20,P＜0.05）.结论 利拉鲁肽可对抗大鼠心肌缺血再灌注损伤,对心肌具有保护作用.其机制可能与抗细胞凋亡和抗氧化作用有关.Objective To explore the effect of liraglutide on myocardial ischemia/reperfusion （I/R） injury in rats and related mechanisms.Methods Twenty-four male SD rats were divided into sham group,I/R injury group,and liraglutide group by table of random number （n =8 each）.Myocardial I/R injury model was established by occlusion of the left anterior descending artery for 30 min followed by 2 h of reperfusion.HE stain method was used to observe cardiomyocyte status under light microscope,myocardial tissue samples were stained with TTC to measure the myocardial infarction size,protein expression of p53 and caspase-3 was analyzed by immunohistochemical technique and Western blot respectively,xanthine oxidase method was used to detect SOD activity,Thiobarbituric acid method was used to measure the concentration of MDA.Results Compared with the I/R group,the degree of myocardial damage of liraglutide group was significantly reduced and the myocardial infarct area was significantly lower （（44 ± 8） ％ vs.（62 ± 8） ％,P ＜ 0.05） while protein expression of caspase-3 and p53 in liraglutide group was significantly downregulated （0.19 ±0.03 vs.0.24 ± 0.02 and 0.27 ± 0.03 vs.0.39 ± 0.04,P ＜ 0.05）.SOD activity was significantly increased and MDA concentration was significantly decreased （74.20 ± 11.10 vs.44.04 ± 14.30 and 4.41 ± 1.07 vs.8.72 ± 2.20,P ＜ 0.05） in liraglutide group compared to I/R group.Conclusion Liraglutide protects myocardium against I/R injury possibly through reducing cardiomyocytes apoptosis and oxidation.

关 键 词：心肌再灌注损伤 利拉鲁肽 

分 类 号：R965[医药卫生—药理学]